Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $43

Benzinga Newsdesk www.benzinga.com Negative 65.5%

Neg 65.5% Neu 0% Pos 0%

Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $45 to $43.